{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:42:27Z","timestamp":1793817747755,"version":"4.6.1"},"reference-count":335,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.addr.2026.115888","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:22:19Z","timestamp":1777875739000},"page":"115888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Overcoming intratumoral transport barriers: Advances in local immunotherapy delivery platforms"],"prefix":"10.1016","volume":"235","author":[{"given":"Madison A.","family":"Deeson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine Ying Xuan","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Grattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115888_bb0005","series-title":"Cancer Facts & Figures 2025","author":"A.C. Society","year":"2025"},{"key":"10.1016\/j.addr.2026.115888_bb0010","unstructured":"PDQ Adult Treatment Editorial Board, PDQ financial toxicity (financial distress) and cancer treatment, National Cancer Institute (2024), https:\/\/www.cancer.gov\/about-cancer\/managing-care\/track-care-costs\/financial-toxicity-pdq. Accessed May 4, 2026.P.D.Q.A.T.E. Board, Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ\u00ae): Patient Version, PDQ Cancer Information Summaries, National Cancer Institute (US), Bethesda (MD), 2002."},{"key":"10.1016\/j.addr.2026.115888_bb0015","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1089\/jpm.2006.9.912","article-title":"Caring for a loved one with advanced cancer: determinants of psychological distress in family caregivers","volume":"9","author":"Dumont","year":"2006","journal-title":"J Palliat Med"},{"key":"10.1016\/j.addr.2026.115888_bb0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/09540261.2017.1288090","article-title":"The burden of psychosocial morbidity related to cancer: patient and family issues","volume":"29","author":"Caruso","year":"2017","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.addr.2026.115888_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: Pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.addr.2026.115888_bb0030","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer \u2014 mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115888_bb0035","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041143","article-title":"Cancer resistance to immunotherapy: Comprehensive insights with future perspectives","volume":"15","author":"Said","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115888_bb0045","doi-asserted-by":"crossref","first-page":"1546717","DOI":"10.3389\/fimmu.2025.1546717","article-title":"Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors","volume":"16","author":"Alsaafeen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0055","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10030655","article-title":"Assessing the future of solid tumor immunotherapy","volume":"10","author":"Guha","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2026.115888_bb0065","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/jamaoncol.2017.4606","article-title":"Efficacy and toxic effects of cancer immunotherapy combinations-A double-edged sword","volume":"4","author":"Tang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0070","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1158\/1078-0432.CCR-19-3642","article-title":"Intratumoral immunotherapy for early-stage solid tumors","volume":"26","author":"Hong","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2026.115888_bb0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.36401\/JIPO-22-8","article-title":"The contemporary landscape and future directions of intratumoral immunotherapy","volume":"6","author":"Brito-Orama","year":"2023","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0080","article-title":"Emerging technologies for local cancer treatment","volume":"3","author":"Chua","year":"2020","journal-title":"Adv Ther (Weinh)"},{"key":"10.1016\/j.addr.2026.115888_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.811485","article-title":"Vascular Microenvironment, Tumor Immunity and Immunotherapy","volume":"12","author":"Lamplugh","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.addr.2026.115888_bb0090","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","article-title":"Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression","volume":"56","author":"Sattiraju","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2026.115888_bb0095","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2026.115888_bb0100","article-title":"Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel-Mediated Reprogramming of Cancer-Associated Fibroblasts in Osteosarcoma","volume":"36","author":"Wang","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.addr.2026.115888_bb0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41419-017-0061-0","article-title":"Defining the role of the tumor vasculature in antitumor immunity and immunotherapy","volume":"9","author":"Schaaf","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.addr.2026.115888_bb0110","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.trecan.2025.04.004","article-title":"Tissue mechanics in tumor heterogeneity and aggression","volume":"11","author":"Finger","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0115","article-title":"An injectable puerarin depot can potentiate chimeric antigen receptor natural killer cell immunotherapy against targeted solid tumors by reversing tumor immunosuppression","volume":"20","author":"Liu","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115888_bb0120","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1021\/acsnano.2c12463","article-title":"Nattokinase-Mediated regulation of tumor physical microenvironment to enhance chemotherapy, radiotherapy, and CAR-T therapy of solid tumor","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0125","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1007\/s13346-021-01036-y","article-title":"Overcoming physical stromal barriers to cancer immunotherapy","volume":"11","author":"Chung","year":"2021","journal-title":"Drug Deliv. Transl Res"},{"key":"10.1016\/j.addr.2026.115888_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.779915","article-title":"Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy","volume":"13","author":"Olsen","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.addr.2026.115888_bb0135","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0140","doi-asserted-by":"crossref","first-page":"1984677","DOI":"10.1080\/2162402X.2021.1984677","article-title":"Trial watch: intratumoral immunotherapy","volume":"10","author":"Humeau","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2026.115888_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007433","article-title":"Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice","volume":"11","author":"Meyblum","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0150","article-title":"277 Safety and efficacy of intratumoral ipilimumab with IV nivolumab in metastatic melanoma. The NIVIPIT trial","volume":"9","author":"Lambros","year":"2021","journal-title":"J. ImmunoTherapy Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0155","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","article-title":"Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance","volume":"42","author":"Bell","year":"2024","journal-title":"Ann. Rev. Immunol."},{"key":"10.1016\/j.addr.2026.115888_bb0160","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/s41590-024-02015-4","article-title":"Next-generation combination approaches for immune checkpoint therapy","volume":"25","author":"Goswami","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb0165","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.21.02067","article-title":"Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study","volume":"40","author":"O'Malley","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.addr.2026.115888_bb0170","first-page":"186","article-title":"Dynamic toxicity landscape of immunotherapy for solid tumors across treatment lines","volume":"3","author":"Liu","year":"2023","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.addr.2026.115888_bb0175","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/S1556-0864(16)30246-5","article-title":"136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial","volume":"11","author":"Ahn","year":"2016","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.addr.2026.115888_bb0180","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0185","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijrobp.2020.07.2326","article-title":"Potentiating antitumor efficacy through radiation and sustained intratumoral delivery of anti-CD40 and Anti-PDL1","volume":"110","author":"Liu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.addr.2026.115888_bb0190","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2026.115888_bb0195","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.addr.2026.115888_bb0200","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdy089","article-title":"Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients","volume":"29","author":"Rodr\u00edguez-Ruiz","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0205","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","article-title":"In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma","volume":"8","author":"Frank","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.addr.2026.115888_bb0210","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.mattod.2023.03.006","article-title":"Hydrogel-enabled, local administration and combinatorial delivery of immunotherapies for cancer treatment","volume":"65","author":"Erfani","year":"2023","journal-title":"Materials Today"},{"key":"10.1016\/j.addr.2026.115888_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/nano13152225","article-title":"Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems","volume":"13","author":"Yun","year":"2023","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.addr.2026.115888_bb0220","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1038\/s41467-024-50967-w","article-title":"An in situ depot for the sustained release of a TLR7\/8 agonist in combination with a TGF\u03b2 inhibitor promotes anti-tumor immune responses","volume":"15","author":"Jensen","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2026.115888_bb0225","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41467-021-27390-6","article-title":"Maximizing response to intratumoral immunotherapy in mice by tuning local retention","volume":"13","author":"Momin","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2026.115888_bb0230","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1158\/1078-0432.CCR-03-0304","article-title":"Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes","volume":"10","author":"van Herpen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2026.115888_bb0235","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: still a promising candidate for tumor immunotherapy?","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.addr.2026.115888_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114505","article-title":"Image-guided intratumoral immunotherapy: Developing a clinically practical technology","volume":"189","author":"Som","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.addr.2026.115888_bb0245","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2026.115888_bb0250","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008287","article-title":"Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C","volume":"12","author":"Gomar","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002432","article-title":"In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models","volume":"9","author":"Oba","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002408","article-title":"Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity","volume":"9","author":"Anfray","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0265","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004799","article-title":"Intratumoral immunotherapy using a TLR2\/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0270","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in Combination with pembrolizumab in advanced melanoma: Results of a Phase Ib","volume":"8","author":"Ribas","year":"2018","journal-title":"Multicenter Study, Cancer Discov"},{"key":"10.1016\/j.addr.2026.115888_bb0275","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232654","article-title":"Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions","volume":"312","author":"Sheth","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.addr.2026.115888_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1385484","article-title":"Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies","volume":"15","author":"Mantooth","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001800","article-title":"Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy","volume":"9","author":"Mu\u00f1oz","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115083","article-title":"Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer","volume":"202","author":"Mikhail","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.addr.2026.115888_bb0295","first-page":"3","article-title":"Acellular scaffold-based approach for in situ genetic engineering of host T-cells in solid tumor immunotherapy","volume":"11","author":"Dandia","year":"2024","journal-title":"Mil Med Res"},{"key":"10.1016\/j.addr.2026.115888_bb0300","doi-asserted-by":"crossref","unstructured":"H.M. Babiker, E.H. Borazanci, V. Subbiah, A. Diab, G. Woodhead, C. Hennemeyer, A.H. Shah, R. Hultsch, R. Murthy, C. Miller, S. Swann, S. Rahimian, J. Geib, M. Catlett, Preliminary safety of deep\/visceral (D\/V) image guided (IG) intratumoral injection (ITI) of IMO-2125, J. Clin. Oncol., 36 e15150.","DOI":"10.1200\/JCO.2018.36.15_suppl.e15150"},{"key":"10.1016\/j.addr.2026.115888_bb0305","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0310","doi-asserted-by":"crossref","first-page":"1479483","DOI":"10.3389\/fimmu.2024.1479483","article-title":"Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer","volume":"15","author":"Skalickova","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2024.04.010","article-title":"Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives","volume":"180","author":"Souto","year":"2024","journal-title":"Acta Biomater"},{"key":"10.1016\/j.addr.2026.115888_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjon.2025.10.032","article-title":"Neoadjuvant intratumoral immune stimulation using gene-mediated cytotoxic immunotherapy for resectable non\u2212small cell lung cancer: 5-Year outcomes","volume":"29","author":"Aicher","year":"2026","journal-title":"JTCVS Open"},{"key":"10.1016\/j.addr.2026.115888_bb0325","first-page":"130","article-title":"Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer, npj","volume":"11","author":"Huppert","year":"2025","journal-title":"Breast Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113761","article-title":"An injectable hydrogel enhances intratumoral retention and antitumor efficacy of cytokine immunotherapy in murine triple negative breast tumor models","volume":"383","author":"Mantooth","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb0335","article-title":"An injectable hydrogel to modulate T cells for cancer immunotherapy","volume":"18","author":"Zhang","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115888_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123000","article-title":"Bacteria-based biohybrids for remodeling adenosine-mediated immunosuppression to boost radiotherapy-triggered antitumor immune response","volume":"316","author":"Wu","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121272","article-title":"Bioadhesive injectable hydrogel with phenolic carbon quantum dot supported Pd single atom nanozymes as a localized immunomodulation niche for cancer catalytic immunotherapy","volume":"280","author":"He","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0350","doi-asserted-by":"crossref","first-page":"9413","DOI":"10.1021\/acsnano.3c11023","article-title":"Bioorthogonal\/ultrasound activated oncolytic pyroptosis amplifies in situ tumor vaccination for boosting antitumor immunity","volume":"18","author":"Xu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0355","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jconrel.2024.12.079","article-title":"Co-activating STING-TLR9 pathways promotes radiotherapy-induced cancer vaccination","volume":"379","author":"Sun","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb0360","doi-asserted-by":"crossref","first-page":"24269","DOI":"10.1021\/acsnano.4c05809","article-title":"Cryo-Nanocatalyst Enhances Therapeutic Efficacy of Cryo-Immunotherapy through Necroptosis and Local Delivery of Programmed Death-Ligand 1 Inhibitors","volume":"18","author":"Lee","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202102781","article-title":"In situ tumor vaccination with calcium-linked degradable coacervate nanocomplex Co-delivering photosensitizer and TLR7\/8 agonist to trigger effective anti-tumor Immune responses","volume":"11","author":"Liu","year":"2022","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.addr.2026.115888_bb0370","doi-asserted-by":"crossref","first-page":"10236","DOI":"10.1021\/acsnano.3c00418","article-title":"In situ vaccination following intratumoral injection of IL2 and Poly-l-lysine\/Iron Oxide\/CpG nanoparticles to a radiated tumor site","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0375","doi-asserted-by":"crossref","first-page":"eabn5859","DOI":"10.1126\/sciimmunol.abn5859","article-title":"Intratumoral immunotherapy relies on B and T cell collaboration","volume":"7","author":"Sagiv-Barfi","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): An intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115888_bb0385","doi-asserted-by":"crossref","first-page":"59682","DOI":"10.1021\/acsami.4c12603","article-title":"Emerging Strategies for Local Delivery of Immune Checkpoint Inhibitors to Potentiate Cancer Immunotherapy: Current Status and Future Prospects","volume":"16","author":"Chen","year":"2024","journal-title":"ACS Appl. Mater Interfaces"},{"key":"10.1016\/j.addr.2026.115888_bb0390","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1632","article-title":"Advances in engineering local drug delivery systems for cancer immunotherapy","volume":"12","author":"Abdou","year":"2020","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.addr.2026.115888_bb0395","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s41565-021-00962-9","article-title":"Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy","volume":"16","author":"Sun","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.addr.2026.115888_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123085","article-title":"Artificially tagging tumors with nano-aluminum adjuvant-tethered antigen mRNA recruits and activates antigen-specific cytotoxic T cells for enhanced cancer immunotherapy","volume":"317","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0405","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jare.2024.03.010","article-title":"Efficient chemo-immunotherapy leveraging minimalist electrostatic complex nanoparticle as \"in situ\" vaccine integrated tumor ICD and immunoagonist","volume":"69","author":"Han","year":"2025","journal-title":"J Adv Res"},{"key":"10.1016\/j.addr.2026.115888_bb0410","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jconrel.2023.01.043","article-title":"Engineered NanoAlum from aluminum turns cold tumor hot for potentiating cancer metalloimmunotherapy","volume":"354","author":"Jia","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb0415","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1021\/acsnano.2c08429","article-title":"Engineered toll-like receptor nanoagonist binding to extracellular matrix elicits safe and robust antitumor immunity","volume":"17","author":"Yang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121762","article-title":"Image-guided in situ cancer vaccination with combination of multi-functional nano-adjuvant and an irreversible electroporation technique","volume":"289","author":"Han","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0425","doi-asserted-by":"crossref","first-page":"15226","DOI":"10.1021\/acsnano.2c06560","article-title":"In situ programming of nanovaccines for lymph node-targeted delivery and cancer immunotherapy","volume":"16","author":"Jin","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0430","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.7150\/thno.74808","article-title":"Intratumoral synthesis of transformable metal-phenolic nanoaggregates with enhanced tumor penetration and retention for photothermal immunotherapy","volume":"12","author":"He","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2026.115888_bb0435","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1038\/s41467-024-48838-5","article-title":"Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery","volume":"15","author":"Zelepukin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115888_bb0440","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb0445","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12951-023-01977-1","article-title":"Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions","volume":"21","author":"Li","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.addr.2026.115888_bb0450","doi-asserted-by":"crossref","first-page":"9935","DOI":"10.1039\/C8NR00640G","article-title":"A size switchable nanoplatform for targeting the tumor microenvironment and deep tumor penetration","volume":"10","author":"Cun","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2026.115888_bb0455","article-title":"Controlled Refolding of Denatured IL-12 Using In Situ Antigen-Capturing Nanochaperone Remarkably Reduces the Systemic Toxicity and Enhances Cancer Immunotherapy","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.addr.2026.115888_bb0460","doi-asserted-by":"crossref","first-page":"14475","DOI":"10.1021\/acsnano.3c00901","article-title":"Ferroptosis and necroptosis produced autologous tumor cell lysates Co-delivering with combined immnoadjuvants as personalized in situ nanovaccines for antitumor immunity","volume":"17","author":"Shi","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0465","article-title":"In Situ Antigen-Capturing Nanochaperone Toward Personalized Nanovaccine for Cancer Immunotherapy","volume":"18","author":"Li","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115888_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.101838","article-title":"Microenvironment-responsive nanocarriers for targeted bone disease therapy","volume":"50","author":"Li","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.addr.2026.115888_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122695","article-title":"Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy","volume":"311","author":"Zhang","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0480","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Materials"},{"key":"10.1016\/j.addr.2026.115888_bb0485","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat Mater"},{"key":"10.1016\/j.addr.2026.115888_bb0490","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jconrel.2024.08.015","article-title":"Predicting tissue distribution and tumor delivery of nanoparticles in mice using machine learning models","volume":"374","author":"Mi","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb0495","doi-asserted-by":"crossref","first-page":"26425","DOI":"10.1021\/acsnano.5c03040","article-title":"Data-Driven Prediction of Nanoparticle Biodistribution from Physicochemical Descriptors","volume":"19","author":"Wu","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0500","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1021\/acsnano.0c01012","article-title":"Reactive Oxygen Species Responsive Theranostic Nanoplatform for Two-Photon Aggregation-Induced Emission Imaging and Therapy of Acute and Chronic Inflammation","volume":"14","author":"Ma","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0505","doi-asserted-by":"crossref","first-page":"1140463","DOI":"10.3389\/fimmu.2023.1140463","article-title":"Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb0510","article-title":"Innovative Strategies in Oncology: Bacterial Membrane Vesicle-Based Drug Delivery Systems for Cancer Diagnosis and Therapy","volume":"17","author":"Li","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115888_bb0515","article-title":"Engineering versatile bacteria-derived outer membrane vesicles: an adaptable platform for advancing cancer immunotherapy","volume":"11","author":"Luo","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.addr.2026.115888_bb0520","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1021\/acsnano.3c00363","article-title":"Cloaking mesoporous polydopamine with bacterial membrane vesicles to amplify local and systemic antitumor immunity","volume":"17","author":"Chen","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304014","article-title":"A bacterial nanomedicine combines photodynamic-immunotherapy and chemotherapy for enhanced treatment of oral squamous cell carcinoma","volume":"19","author":"Shi","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115888_bb0530","article-title":"Antigen capture and immune modulation by bacterial outer membrane vesicles as in situ vaccine for cancer immunotherapy post-photothermal therapy","volume":"18","author":"Li","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115888_bb0535","doi-asserted-by":"crossref","first-page":"24947","DOI":"10.1021\/acsnano.3c06784","article-title":"Dendritic cell-based in situ nanovaccine for reprogramming lipid metabolism to boost tumor immunotherapy","volume":"17","author":"Qin","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0540","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1021\/acsnano.3c13194","article-title":"Programmed nanocloak of commensal bacteria-derived nanovesicles amplify strong immunoreactivity against tumor growth and metastatic progression","volume":"18","author":"Zhang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0545","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202103505","article-title":"Physical disruption of solid tumors by immunostimulatory microrobots enhances antitumor immunity","volume":"33","author":"Zhou","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.addr.2026.115888_bb0550","article-title":"ATP-responsive manganese-based bacterial materials synergistically activate the cGAS-STING pathway for tumor immunotherapy","volume":"36","author":"Yang","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.addr.2026.115888_bb0555","article-title":"Decorating bacteria with triple immune nanoactivators generates tumor-resident living immunotherapeutics","volume":"61","author":"Li","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.addr.2026.115888_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121332","article-title":"Engineering bioluminescent bacteria to boost photodynamic therapy and systemic anti-tumor immunity for synergistic cancer treatment","volume":"281","author":"Yang","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123037","article-title":"In situ production and precise release of bioactive GM-CSF and siRNA by engineered bacteria for macrophage reprogramming in cancer immunotherapy","volume":"317","author":"Wang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0570","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41586-021-04003-2","article-title":"Metabolic modulation of tumours with engineered bacteria for immunotherapy","volume":"598","author":"Canale","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115888_bb0575","doi-asserted-by":"crossref","first-page":"15648","DOI":"10.1038\/s41598-021-95157-6","article-title":"MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model","volume":"11","author":"de Queiroz","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.addr.2026.115888_bb0580","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1021\/acsnano.4c13320","article-title":"Orthogonally engineered bacteria capture metabolically labeled tumor antigens to improve the systemic immune response in irradiated tumors","volume":"19","author":"Xia","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0585","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.add7034","article-title":"Probiotic-guided CAR-T cells for solid tumor targeting","volume":"382","author":"Vincent","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115888_bb0590","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adn9879","article-title":"Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms","volume":"9","author":"Li","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb0595","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fonc.2018.00136","article-title":"Attenuated bacteria as immunotherapeutic tools for cancer treatment","volume":"8","author":"Kaimala","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0600","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1038\/s41467-022-35130-7","article-title":"Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2026.115888_bb0605","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433989","article-title":"IL-2 based cancer immunotherapies: an evolving paradigm","volume":"15","author":"Rokade","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115888_bb0610","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/1078-0432.CCR-20-2065","article-title":"Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors","volume":"27","author":"Janku","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2026.115888_bb0615","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.addr.2026.115888_bb0620","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduction Targeted Therapy"},{"key":"10.1016\/j.addr.2026.115888_bb0625","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12935-024-03424-z","article-title":"Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments","volume":"24","author":"Yan","year":"2024","journal-title":"Cancer Cell International"},{"key":"10.1016\/j.addr.2026.115888_bb0630","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.addr.2026.115888_bb0635","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003490","article-title":"Oncolytic adenovirus decreases the proportion of TIM-3(+) subset of tumor-infiltrating CD8(+) T cells with correlation to improved survival in patients with cancer","volume":"10","author":"Liikanen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0640","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008431","article-title":"An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0645","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.addr.2026.115888_bb0650","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009581","article-title":"Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy","volume":"12","author":"Lenga","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0655","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0660","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115888_bb0665","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2026.115888_bb0670","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","article-title":"Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1","volume":"7","author":"Thomas","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb0675","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/s41388-025-03357-5","article-title":"Deciphering permissivity of human tumor ecosystems to oncolytic viruses","volume":"44","author":"Schoeps","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2026.115888_bb0680","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.ymthe.2025.03.035","article-title":"Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation","volume":"33","author":"Alwithenani","year":"2025","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.addr.2026.115888_bb0685","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent Glioblastoma Treated with Recombinant Poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.addr.2026.115888_bb0690","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/neuonc\/nop054","article-title":"Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma","volume":"12","author":"Kunwar","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0695","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/neuonc\/noac285","article-title":"Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial","volume":"25","author":"Sampson","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0700","doi-asserted-by":"crossref","first-page":"eabn5649","DOI":"10.1126\/scitranslmed.abn5649","article-title":"Immunotoxin-\u03b1CD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models","volume":"15","author":"Parker","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.addr.2026.115888_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105202","article-title":"Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice","volume":"105","author":"Roncali","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2026.115888_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122006","article-title":"Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival","volume":"294","author":"Catania","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0715","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1038\/s41467-025-59971-0","article-title":"FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma","volume":"16","author":"Beffinger","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2026.115888_bb0720","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s43246-024-00721-y","article-title":"Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma","volume":"6","author":"Mokarram","year":"2025","journal-title":"Commun Mater"},{"key":"10.1016\/j.addr.2026.115888_bb0725","doi-asserted-by":"crossref","first-page":"9342796","DOI":"10.1155\/2019\/9342796","article-title":"Convection-Enhanced Delivery in Malignant Gliomas: A Review of Toxicity and Efficacy","volume":"2019","author":"Shi","year":"2019","journal-title":"J Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0730","article-title":"Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma","volume":"5","author":"Sperring","year":"2023","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.addr.2026.115888_bb0735","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-020-03408-9","article-title":"Convection-enhanced drug delivery for glioblastoma: a review","volume":"151","author":"D'Amico","year":"2021","journal-title":"J Neurooncol"},{"key":"10.1016\/j.addr.2026.115888_bb0740","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s13311-017-0520-4","article-title":"Convection-enhanced delivery","volume":"14","author":"Mehta","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.addr.2026.115888_bb0745","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.3171\/foc.2006.20.4.9","article-title":"Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies","volume":"20","author":"Sampson","year":"2006","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.addr.2026.115888_bb0750","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ijrobp.2007.01.065","article-title":"Convection-enhanced delivery of an iodine tracer into rat brain for synchrotron stereotactic radiotherapy","volume":"68","author":"Rousseau","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.addr.2026.115888_bb0755","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-21-3324","article-title":"Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: A phase I clinical trial including correlative studies","volume":"28","author":"van Putten","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2026.115888_bb0760","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/neuonc\/nou354","article-title":"Convection-enhanced delivery for the treatment of glioblastoma","volume":"17 Suppl 2","author":"Vogelbaum","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0765","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3171\/2020.6.PEDS20280","article-title":"Repeat convection-enhanced delivery for diffuse intrinsic pontine glioma","volume":"26","author":"Bander","year":"2020","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.addr.2026.115888_bb0770","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3171\/2014.10.JNS14229","article-title":"Convection-enhanced delivery to the central nervous system","volume":"122","author":"Lonser","year":"2015","journal-title":"J Neurosurg"},{"key":"10.1016\/j.addr.2026.115888_bb0775","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(22)00599-X","article-title":"Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial","volume":"23","author":"Spinazzi","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb0780","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1007\/s13346-021-01008-2","article-title":"Overcoming delivery barriers in immunotherapy for glioblastoma","volume":"11","author":"Rui","year":"2021","journal-title":"Drug Deliv. Transl Res"},{"key":"10.1016\/j.addr.2026.115888_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.device.2023.100068","article-title":"Implantable microdevices for treating brain tumors","volume":"1","author":"Yearley","year":"2023","journal-title":"Device"},{"key":"10.1016\/j.addr.2026.115888_bb0790","doi-asserted-by":"crossref","DOI":"10.3390\/ph15111430","article-title":"Osmotic Pump Drug Delivery Systems-A Comprehensive Review","volume":"15","author":"Almoshari","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.addr.2026.115888_bb0795","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13046-025-03393-9","article-title":"7aaRGD - a novel SPP1\/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas","volume":"44","author":"Ellert-Miklaszewska","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.addr.2026.115888_bb0800","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0023677220939991","article-title":"Comparison of the effects of osmotic pump implantation with subcutaneous injection for administration of drugs after total body irradiation in mice","volume":"55","author":"Koch","year":"2021","journal-title":"Lab Anim"},{"key":"10.1016\/j.addr.2026.115888_bb0805","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/2019.10.FOCUS19703","article-title":"Evaluating infusate parameters for direct drug delivery to the brainstem: a comparative study of convection-enhanced delivery versus osmotic pump delivery","volume":"48","author":"Rechberger","year":"2020","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.addr.2026.115888_bb0810","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jare.2013.07.006","article-title":"Hydrogel: Preparation, characterization, and applications: A review","volume":"6","author":"Ahmed","year":"2015","journal-title":"J Adv Res"},{"key":"10.1016\/j.addr.2026.115888_bb0815","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejpb.2007.02.025","article-title":"Thermoresponsive hydrogels in biomedical applications","volume":"68","author":"Klouda","year":"2008","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.addr.2026.115888_bb0820","doi-asserted-by":"crossref","DOI":"10.3390\/gels9070523","article-title":"Polymer-based hydrogels applied in drug delivery: An overview","volume":"9","author":"Thang","year":"2023","journal-title":"Gels"},{"key":"10.1016\/j.addr.2026.115888_bb0825","doi-asserted-by":"crossref","first-page":"23838","DOI":"10.1039\/D0NR05053A","article-title":"Intratumoral injection of hydrogel-embedded nanoparticles enhances retention in glioblastoma","volume":"12","author":"Brachi","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2026.115888_bb0830","doi-asserted-by":"crossref","DOI":"10.3390\/gels9100838","article-title":"Current advances in stimuli-responsive hydrogels as smart drug delivery carriers","volume":"9","author":"Zhang","year":"2023","journal-title":"Gels"},{"key":"10.1016\/j.addr.2026.115888_bb0835","article-title":"Engineering ROS-responsive bioscaffolds for disrupting myeloid cell-driven immunosuppressive niche to enhance PD-L1 blockade-based postablative immunotherapy","volume":"9","author":"Li","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.addr.2026.115888_bb0840","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jconrel.2024.06.052","article-title":"Environmentally responsive hydrogel promotes vascular normalization to enhance STING anti-tumor immunity","volume":"372","author":"Wang","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb0845","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jconrel.2024.08.043","article-title":"In situ formed reactive oxygen species-responsive dipyridamole prodrug hydrogel: Spatiotemporal drug delivery for chemoimmunotherapy","volume":"375","author":"Xiao","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb0850","article-title":"In situ formed ROS-responsive hydrogel with STING agonist and gemcitabine to intensify immunotherapy against pancreatic ductal adenocarcinoma","volume":"12","author":"Wang","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.addr.2026.115888_bb0855","article-title":"In situ tumor vaccine for lymph nodes delivery and cancer therapy based on small size nanoadjuvant","volume":"19","author":"Zhang","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115888_bb0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122740","article-title":"An ultra-long-acting L-asparaginase synergizes with an immune checkpoint inhibitor in starvation-immunotherapy of metastatic solid tumors","volume":"312","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0865","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jconrel.2023.12.002","article-title":"Antigen-specific T cell activation through targeted delivery of in-situ generated antigen and calcium ionophore to enhance antitumor immunotherapy","volume":"365","author":"Chen","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb0870","article-title":"Biomimetic hydrogel-mediated mechano-immunometabolic therapy for inhibition of ccRCC recurrence after surgery","volume":"11","author":"Dong","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.addr.2026.115888_bb0875","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202301083","article-title":"EISA in tandem with ICD to form in situ nanofiber vaccine for enhanced tumor radioimmunotherapy","volume":"12","author":"Luo","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.addr.2026.115888_bb0880","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1021\/acsnano.2c10845","article-title":"Extracellular matrix viscosity reprogramming by in situ Au bioreactor-boosted microwavegenetics disables tumor escape in CAR-T immunotherapy","volume":"17","author":"Wang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123201","article-title":"Immunogenic cuproptosis in cancer immunotherapy via an in situ cuproptosis-inducing system","volume":"319","author":"Li","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0890","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jconrel.2022.03.050","article-title":"In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma","volume":"345","author":"Wang","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb0895","article-title":"In Situ vaccination with an injectable nucleic acid hydrogel for synergistic cancer immunotherapy","volume":"63","author":"Wang","year":"2024","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.addr.2026.115888_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122189","article-title":"Injectable cold atmospheric plasma-activated immunotherapeutic hydrogel for enhanced cancer treatment","volume":"300","author":"Fang","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0905","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12951-024-02646-7","article-title":"Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic treatment of pancreatic ductal adenocarcinoma","volume":"22","author":"Zhou","year":"2024","journal-title":"J Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115888_bb0910","doi-asserted-by":"crossref","first-page":"13352","DOI":"10.1038\/s41598-024-64189-z","article-title":"X-ray imageable, drug-loaded hydrogel that forms at body temperature for image-guided, needle-based locoregional drug delivery","volume":"14","author":"Delgado","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.addr.2026.115888_bb0915","doi-asserted-by":"crossref","DOI":"10.3390\/gels8050301","article-title":"Current understanding of hydrogel for drug release and tissue engineering","volume":"8","author":"Lei","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.addr.2026.115888_bb0920","doi-asserted-by":"crossref","DOI":"10.3390\/ma17194792","article-title":"Cutting-Edge Hydrogel Technologies in Tissue Engineering and Biosensing: An Updated Review","volume":"17","author":"Parvin","year":"2024","journal-title":"Materials (Basel)"},{"key":"10.1016\/j.addr.2026.115888_bb0925","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-024-01852-x","article-title":"Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.addr.2026.115888_bb0930","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202416813","article-title":"Implantable Biomaterials for Cancer Immunotherapies","volume":"35","author":"Pechnikova","year":"2025","journal-title":"Adv. Functional Materials"},{"key":"10.1016\/j.addr.2026.115888_bb0935","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.612950","article-title":"Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy","volume":"8","author":"Li","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2026.115888_bb0940","article-title":"Prophylactic and therapeutic cancer vaccine with continuous localized immunomodulation","volume":"62","author":"Kota","year":"2024","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2026.115888_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121374","article-title":"Engineered implantable vaccine platform for continuous antigen-specific immunomodulation","volume":"281","author":"Viswanath","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0950","unstructured":"A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients, 2012."},{"key":"10.1016\/j.addr.2026.115888_bb0955","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2024.04.040","article-title":"Biomaterial-based scaffolds for direct in situ programming of tumor-infiltrating T lymphocytes","volume":"370","author":"Inamdar","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122580","article-title":"Implantable CAR T cell factories enhance solid tumor treatment","volume":"308","author":"Pandit","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb0965","doi-asserted-by":"crossref","first-page":"17653","DOI":"10.1021\/acsnano.5c01366","article-title":"An implantable double-layered spherical scaffold depositing gene and cell agents to facilitate collaborative cancer immunotherapy","volume":"19","author":"Lei","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb0970","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41578-023-00617-2","article-title":"Responsive biomaterials: optimizing control of cancer immunotherapy","volume":"9","author":"Xue","year":"2024","journal-title":"Nat. Rev. Materials"},{"key":"10.1016\/j.addr.2026.115888_bb0975","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2018.06.035","article-title":"Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer","volume":"285","author":"Chua","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb0980","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10594","article-title":"Intratumoral nanofluidic system enhanced tumor biodistribution of PD-L1 antibody in triple-negative breast cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.addr.2026.115888_bb0985","article-title":"Sustained intratumoral administration of agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer","volume":"10","author":"Liu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.addr.2026.115888_bb0990","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202302410","article-title":"Exploiting unique features of microneedles to modulate immunity","volume":"35","author":"Edwards","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.addr.2026.115888_bb0995","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jconrel.2025.02.003","article-title":"Microneedle-based nanodrugs for tumor immunotherapy","volume":"380","author":"Wang","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb1000","article-title":"Dissolvable self-locking microneedle patches integrated with immunomodulators for cancer immunotherapy","volume":"35","author":"Joo","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.addr.2026.115888_bb1005","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030744","article-title":"Microneedles for efficient and precise drug delivery in cancer therapy","volume":"15","author":"Ganeson","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115888_bb1010","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1007\/s13346-023-01297-9","article-title":"Microneedle-mediated treatment for superficial tumors by combining multiple strategies","volume":"13","author":"Wang","year":"2023","journal-title":"Drug Delivery Translational Res."},{"key":"10.1016\/j.addr.2026.115888_bb1015","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/17425247.2022.2084070","article-title":"Intratumorally anchored cytokine therapy","volume":"19","author":"Wittrup","year":"2022","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.addr.2026.115888_bb1020","doi-asserted-by":"crossref","first-page":"eabo3603","DOI":"10.1126\/scitranslmed.abo3603","article-title":"In vivo gene immunotherapy for cancer","volume":"14","author":"Mai","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.addr.2026.115888_bb1025","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091861","article-title":"Plasmid DNA for therapeutic applications in cancer","volume":"14","author":"Mart\u00ednez-Puente","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115888_bb1030","doi-asserted-by":"crossref","first-page":"17635","DOI":"10.1021\/acsnano.1c05420","article-title":"Genome-editing-mediated restructuring of tumor immune microenvironment for prevention of metastasis","volume":"15","author":"Kim","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb1035","article-title":"Injectable supramolecular hydrogels for in situ programming of Car-T cells toward solid tumor immunotherapy","volume":"36","author":"Zhu","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.addr.2026.115888_bb1040","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2024.03.018","article-title":"Plasmid DNA ionisable lipid nanoparticles as non-inert carriers and potent immune activators for cancer immunotherapy","volume":"369","author":"Qin","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb1045","first-page":"62","article-title":"Macromolecular Gene Delivery Systems: Advancing Non-viral Therapeutics with Synthetic and Natural Polymers","volume":"10","author":"Panda","year":"2025","journal-title":"J. Exploratory Res. Pharmacol."},{"key":"10.1016\/j.addr.2026.115888_bb1050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/14760584.2023.2292772","article-title":"The use of electroporation to deliver DNA-based vaccines","volume":"23","author":"Kisakov","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2026.115888_bb1060","doi-asserted-by":"crossref","first-page":"1321318","DOI":"10.3389\/fonc.2023.1321318","article-title":"Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine","volume":"13","author":"Minnar","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb1065","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-19-2217","article-title":"Phase II trial of IL-12 Plasmid transfection and PD-1 blockade in immunologically quiescent melanoma","volume":"26","author":"Algazi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2026.115888_bb1070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1075","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1021\/acs.nanolett.2c01994","article-title":"Injectable immunotherapeutic hydrogel containing RNA-loaded lipid nanoparticles reshapes tumor microenvironment for pancreatic cancer therapy","volume":"22","author":"Gao","year":"2022","journal-title":"Nano Lett"},{"key":"10.1016\/j.addr.2026.115888_bb1080","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb1085","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41423-021-00786-6","article-title":"The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy","volume":"19","author":"Zheng","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb1090","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduction Targeted Therapy"},{"key":"10.1016\/j.addr.2026.115888_bb1095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1039\/D5PM00159E","article-title":"mRNA therapeutics beyond vaccines: dosing precision challenges and clinical translation framework","volume":"3","author":"Niazi","year":"2026","journal-title":"RSC Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115888_bb1100","article-title":"A Comparison of plasmid DNA and mRNA as vaccine technologies","volume":"7","author":"Liu","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2026.115888_bb1105","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf115","article-title":"First-in-human phase I\/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer","volume":"30","author":"Sullivan","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.addr.2026.115888_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115306","article-title":"Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade","volume":"209","author":"Choi","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.addr.2026.115888_bb1115","article-title":"In Situ Cocktail Nanovaccine for Cancer Immunotherapy","volume":"10","author":"Liu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.addr.2026.115888_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106981","article-title":"A journey into siRNA therapeutics development: A focus on Pharmacokinetics and Pharmacodynamics","volume":"205","author":"Choi","year":"2025","journal-title":"European J. Pharmaceutical Sci."},{"key":"10.1016\/j.addr.2026.115888_bb1125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-024-02112-8","article-title":"Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduction Targeted Therapy"},{"key":"10.1016\/j.addr.2026.115888_bb1130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","article-title":"Engineering siRNA therapeutics: challenges and strategies","volume":"21","author":"Ali Zaidi","year":"2023","journal-title":"Journal of Nanobiotechnology"},{"key":"10.1016\/j.addr.2026.115888_bb1135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087453","article-title":"CRIF1 siRNA-Encapsulated PLGA Nanoparticles Suppress Tumor Growth in MCF-7 Human Breast Cancer Cells","volume":"24","author":"Piao","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.addr.2026.115888_bb1140","doi-asserted-by":"crossref","first-page":"1501679","DOI":"10.3389\/fimmu.2024.1501679","article-title":"Self-delivering RNAi immunotherapeutic PH-762 silences PD-1 to generate local and abscopal antitumor efficacy","volume":"15","author":"Cuiffo","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb1145","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/14712598.2021.1902982","article-title":"Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer","volume":"21","author":"Collins","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.addr.2026.115888_bb1150","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacological Sci."},{"key":"10.1016\/j.addr.2026.115888_bb1155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/104303403321070810","article-title":"Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors","volume":"14","author":"Wang","year":"2003","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.addr.2026.115888_bb1160","first-page":"2595","article-title":"A phase I\/II study of herpes simplex virus type 1 thymidine kinase \"suicide\" gene therapy for recurrent glioblastoma","volume":"9","author":"Klatzmann","year":"1998","journal-title":"Study Group on Gene Therapy for Glioblastoma, Hum Gene Ther"},{"key":"10.1016\/j.addr.2026.115888_bb1165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9784","article-title":"Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma","volume":"8","author":"Cloughesy","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.addr.2026.115888_bb1170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.addr.2026.115888_bb1175","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16050981","article-title":"Dendritic Cells in Cancer Immunology and Immunotherapy","volume":"16","author":"Hato","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115888_bb1180","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006896","article-title":"Dubinett, CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity","volume":"11","author":"Salehi-Rad","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1185","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1038\/s41467-025-59840-w","article-title":"Integrating antigen capturing nanoparticles and type 1 conventional dendritic cell therapy for in situ cancer immunization","volume":"16","author":"Chao","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2026.115888_bb1190","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","article-title":"Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8(+) T-cell Infiltration","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.addr.2026.115888_bb1195","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008148","article-title":"Intratumoral administration of the immunologic adjuvant AS01(B) in combination with autologous CD1c (BDCA-1)(+)\/CD141 (BDCA-3)(+) myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma","volume":"12","author":"Tijtgat","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1200","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.ijrobp.2010.12.068","article-title":"Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients","volume":"82","author":"Finkelstein","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.addr.2026.115888_bb1205","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jamaoncol.2024.5371","article-title":"Alteration of the tumor microenvironment with intratumoral dendritic cells before chemotherapy in ERBB2 breast cancer: A nonrandomized clinical trial","volume":"11","author":"Han","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb1210","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1652329","article-title":"Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors","volume":"15","author":"Guo","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb1215","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb1220","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn8264","article-title":"Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors","volume":"8","author":"Grosskopf","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.addr.2026.115888_bb1225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1638186","article-title":"Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling","volume":"16","author":"Andreou","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb1230","first-page":"1152","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer, Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.addr.2026.115888_bb1235","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.addr.2026.115888_bb1240","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007162","article-title":"Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study","volume":"11","author":"Papa","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1245","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12943-024-02064-1","article-title":"Decoding the spatiotemporal heterogeneity of tumor-associated macrophages","volume":"23","author":"Chu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1250","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1038\/s41467-025-59326-9","article-title":"CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation","volume":"16","author":"Chen","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2026.115888_bb1255","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202307694","article-title":"Nanoengineered macrophages armed with TLR7\/8 agonist enhance remodeling of immunosuppressive tumor microenvironment","volume":"20","author":"Yoo","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115888_bb1260","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nature Med."},{"key":"10.1016\/j.addr.2026.115888_bb1265","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: function, regulation and therapeutic potential","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.addr.2026.115888_bb1270","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/annonc\/mdx179","article-title":"Pattern recognition receptors: immune targets to enhance cancer immunotherapy","volume":"28","author":"Shekarian","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb1275","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.immuni.2023.07.018","article-title":"Targeting innate immune pathways for cancer immunotherapy","volume":"56","author":"Cao","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2026.115888_bb1280","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004464","article-title":"Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy","volume":"10","author":"Groeneveldt","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1285","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1021\/acsnano.3c10225","article-title":"Radiotherapy-Triggered In Situ Tumor Vaccination Boosts Checkpoint Blockaded Immune Response via Antigen-Capturing Nanoadjuvants","volume":"18","author":"Xu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb1290","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12951-022-01577-5","article-title":"Sequential acid\/reduction response of triblock copolymeric nanomicelles to release camptothecin and toll-like receptor 7\/8 agonist for orchestrated chemoimmunotherapy","volume":"20","author":"Ge","year":"2022","journal-title":"J Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115888_bb1295","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1021\/acs.molpharmaceut.4c00875","article-title":"Polyinosinic\/polycytidylic lipid nanoparticles enhance immune cell infiltration and improve survival in the glioblastoma mouse model","volume":"21","author":"Br\u00fc\u00dfeler","year":"2024","journal-title":"Mol Pharm"},{"key":"10.1016\/j.addr.2026.115888_bb1300","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jconrel.2024.01.033","article-title":"Risedronate-functionalized manganese-hydroxyapatite amorphous particles: A potent adjuvant for subunit vaccines and cancer immunotherapy","volume":"367","author":"Zhang","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb1305","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202407914","article-title":"Sulfate radical based In situ vaccine boosts systemic antitumor immunity via concurrent activation of necroptosis and STING pathway","volume":"36","author":"Huang","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.addr.2026.115888_bb1310","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade6257","article-title":"Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect","volume":"9","author":"Cheng","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.addr.2026.115888_bb1315","article-title":"Overcoming chemoimmunotherapy-induced immunosuppression by assemblable and depot forming immune modulating nanosuspension","volume":"8","author":"Jin","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.addr.2026.115888_bb1320","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002953","article-title":"Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy","volume":"9","author":"Alvarez","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1325","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202301269","article-title":"Immuno-nanozymes mediated synergistic chemodynamic\/immuno-therapy with potentiated anti-tumor efficacy","volume":"12","author":"Yin","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.addr.2026.115888_bb1330","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase ib, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.addr.2026.115888_bb1335","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011651","article-title":"Phase 1b\/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors","volume":"13","author":"Milhem","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1340","first-page":"720","article-title":"Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial, Cancer","volume":"2","author":"Salazar","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.addr.2026.115888_bb1345","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/10428194.2021.2010057","article-title":"Phase 1\/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma","volume":"63","author":"Halwani","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.addr.2026.115888_bb1350","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004218","article-title":"Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7\/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT","volume":"10","author":"Rolig","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1355","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00262-022-03191-8","article-title":"Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies","volume":"71","author":"Moreno","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.addr.2026.115888_bb1360","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO-24-02595","article-title":"BO-112 plus pembrolizumab for patients with anti-PD-1-resistant advanced melanoma: phase II clinical trial SPOTLIGHT-203","volume":"43","author":"M\u00e1rquez-Rodas","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb1365","article-title":"Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives","volume":"28","author":"Salazar","year":"2025","journal-title":"Immuno-Oncol. Technol."},{"key":"10.1016\/j.addr.2026.115888_bb1370","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1456658","article-title":"Intratumoral injection and retention hold promise to improve cytokine therapies for cancer","volume":"14","author":"Sauer","year":"2024","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.addr.2026.115888_bb1375","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/s41590-024-01925-7","article-title":"Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity","volume":"25","author":"Santollani","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb1380","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm9043","article-title":"NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity","volume":"14","author":"Kirchhammer","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.addr.2026.115888_bb1385","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk7695","article-title":"Noncovalently particle-anchored cytokines with prolonged tumor retention safely elicit potent antitumor immunity","volume":"10","author":"Niu","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115888_bb1390","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2478\/raon-2022-0021","article-title":"Treatment of skin tumors with intratumoral interleukin 12 gene electrotransfer in the head and neck region: a first-in-human clinical trial protocol","volume":"56","author":"Groselj","year":"2022","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.addr.2026.115888_bb1395","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb1400","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1405","doi-asserted-by":"crossref","first-page":"649","DOI":"10.20892\/j.issn.2095-3941.2020.0704","article-title":"Strategies to enhance monoclonal antibody uptake and distribution in solid tumors","volume":"18","author":"Bordeau","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.addr.2026.115888_bb1410","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1021\/acsnano.2c12313","article-title":"Bioorthogonal activation of TLR7 agonists provokes innate immunity to reinforce aptamer-based checkpoint blockade","volume":"17","author":"Wei","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb1415","article-title":"Engineering Modular Peptide Nanoparticles for Ferroptosis-Enhanced Tumor Immunotherapy","volume":"64","author":"Wu","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.addr.2026.115888_bb1420","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jconrel.2025.01.055","article-title":"In situ vaccine \"seeds\" for enhancing cancer immunotherapy by exploiting apoptosis-associated morphological changes","volume":"379","author":"Wang","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb1425","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12951-022-01270-7","article-title":"Inhibition of post-surgery tumour recurrence via a sprayable chemo-immunotherapy gel releasing PD-L1 antibody and platelet-derived small EVs","volume":"20","author":"Zhao","year":"2022","journal-title":"J Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115888_bb1430","doi-asserted-by":"crossref","first-page":"15881","DOI":"10.1021\/acsami.1c22479","article-title":"Intratumoral Anti-PD-1 Nanoformulation Improves Its Biodistribution","volume":"14","author":"Badiee","year":"2022","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.addr.2026.115888_bb1435","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1186\/s12885-018-4764-0","article-title":"'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment","volume":"18","author":"Rotman","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1440","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s41401-024-01304-w","article-title":"Targeting metabolism to enhance immunotherapy within tumor microenvironment","volume":"45","author":"Liang","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.addr.2026.115888_bb1445","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","article-title":"Cancer cell metabolism and antitumour immunity","volume":"24","author":"De Martino","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb1450","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41573-025-01227-z","article-title":"Metabolites as agents and targets for cancer immunotherapy","volume":"24","author":"Trefny","year":"2025","journal-title":"Nature Rev. Drug Discovery"},{"key":"10.1016\/j.addr.2026.115888_bb1455","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jconrel.2025.02.027","article-title":"A lipid starvation strategy-synergized neutrophil activation for postoperative melanoma immunotherapy","volume":"380","author":"Zhao","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb1460","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1038\/s41467-022-31579-8","article-title":"An in situ hydrogel-mediated chemo-immunometabolic cancer therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2026.115888_bb1465","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb1470","article-title":"Immunomodulatory effects of photothermal therapy in breast cancer: advances and challenges","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb1475","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41392-025-02140-y","article-title":"Phototherapy in cancer treatment: strategies and challenges","volume":"10","author":"Cai","year":"2025","journal-title":"Signal Transduction Targeted Therapy"},{"key":"10.1016\/j.addr.2026.115888_bb1480","article-title":"Exploring the application of metal-based photothermal agents in photothermal therapy combined with immune checkpoint therapy","volume":"16","author":"Xie","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.addr.2026.115888_bb1485","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1021\/acsnano.3c05829","article-title":"In situ nanofiber patch boosts postoperative hepatocellular carcinoma immune activation by trimodal combination therapy","volume":"18","author":"Zhao","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb1490","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202307193","article-title":"Laser-activatable in situ vaccine enhances cancer-immunity cycle","volume":"35","author":"Wang","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.addr.2026.115888_bb1495","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1186\/s12951-024-02944-0","article-title":"Photoimmunotherapy using indocyanine green-loaded Codium fragile polysaccharide and chitosan nanoparticles suppresses tumor growth and metastasis","volume":"22","author":"Ryu","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.addr.2026.115888_bb1500","doi-asserted-by":"crossref","first-page":"32088","DOI":"10.1021\/acsnano.4c10688","article-title":"Potent Amphiphilic poly(amino acid) nanoadjuvant delivers biomineralized ovalbumin for photothermal-augmented immunotherapy","volume":"18","author":"Zhao","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb1505","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121233","article-title":"Synergistic photothermal cancer immunotherapy by Cas9 ribonucleoprotein-based copper sulfide nanotherapeutic platform targeting PTPN2","volume":"279","author":"Yan","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb1510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2024.01.035","article-title":"ATP-adenosine axis regulation combined with microneedle assisted photoimmunotherapy to boost the immunotherapy efficiency","volume":"367","author":"Shi","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2026.115888_bb1515","article-title":"Living hybrid material based on probiotic with photothermal properties inhibits PD-L1 expression after tumouricidal photothermal therapy","volume":"6","author":"Jiang","year":"2025","journal-title":"BMT"},{"key":"10.1016\/j.addr.2026.115888_bb1520","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112175","article-title":"Advancements in microwave ablation for tumor treatment and future directions","volume":"28","author":"Dong","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.addr.2026.115888_bb1525","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jvir.2023.10.033","article-title":"Synergizing thermal ablation modalities with immunotherapy: enough to induce systemic antitumoral immunity?","volume":"35","author":"Mustafa","year":"2024","journal-title":"J. Vasc. Interv. Radiol."},{"key":"10.1016\/j.addr.2026.115888_bb1530","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinimag.2023.110070","article-title":"Efficacy and safety of microwave ablation and its synergistic potential in the treatment of early-stage non-small cell lung cancer","volume":"107","author":"Hu","year":"2024","journal-title":"Clin. Imaging"},{"key":"10.1016\/j.addr.2026.115888_bb1535","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101859","article-title":"Contribution of immune cells in synergistic anti-tumor effect of ablation and immunotherapy","volume":"40","author":"He","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.addr.2026.115888_bb1540","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s44222-024-00257-3","article-title":"Imaging-guided precision hyperthermia with magnetic nanoparticles","volume":"3","author":"Shakeri-Zadeh","year":"2025","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.addr.2026.115888_bb1545","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2025.102070","article-title":"Magnetic hyperthermia in oncology: Nanomaterials-driven combinatorial strategies for synergistic therapeutic gains","volume":"33","author":"Xiong","year":"2025","journal-title":"Materials Today Bio"},{"key":"10.1016\/j.addr.2026.115888_bb1550","article-title":"Amplifying cancer treatment: advances in tumor immunotherapy and nanoparticle-based hyperthermia","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115888_bb1555","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1247268","article-title":"Mechanisms and applications of radiation-induced oxidative stress in regulating cancer immunotherapy","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115888_bb1560","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12964-023-01139-8","article-title":"Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations","volume":"21","author":"Wu","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.addr.2026.115888_bb1565","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1554499","article-title":"Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application","volume":"16","author":"Jiang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115888_bb1570","series-title":"A Phase I\/II study of intratumoral injection of rhuFlt3L\/CDX-301 and Poly-ICLC in combination with low-dose radiotherapy in low-grade B-cell lymphomas","year":"2013"},{"key":"10.1016\/j.addr.2026.115888_bb1575","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41416-024-02898-y","article-title":"The abscopal effects of sonodynamic therapy in cancer","volume":"132","author":"Collins","year":"2025","journal-title":"British J. Cancer"},{"key":"10.1016\/j.addr.2026.115888_bb1580","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.scib.2025.03.015","article-title":"Oxygen\/sulfate radicals-generating CaS(2)O(8) nanosonosensitizers induce PANoptosis and calcium overload for enhanced peritoneal metastasis immunotherapy","volume":"70","author":"Wang","year":"2025","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.addr.2026.115888_bb1585","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1021\/acsami.4c21975","article-title":"Acoustically driven hybrid nanocrystals for in vivo pancreatic cancer treatment","volume":"17","author":"Conte","year":"2025","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.addr.2026.115888_bb1590","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091332","article-title":"Photodynamic therapy review: principles, photosensitizers, applications, and future directions","volume":"13","author":"Correia","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115888_bb1595","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030585","article-title":"The current status of photodynamic therapy in cancer treatment","volume":"15","author":"Jiang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115888_bb1600","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1375767","article-title":"Enhancing cancer immunotherapy with photodynamic therapy and nanoparticle: making tumor microenvironment hotter to make immunotherapeutic work better","volume":"15","author":"Thiruppathi","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.addr.2026.115888_bb1605","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121167","article-title":"Cancer immunogenic cell death via photo-pyroptosis with light-sensitive Indoleamine 2,3-dioxygenase inhibitor conjugate","volume":"278","author":"Lu","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115888_bb1610","doi-asserted-by":"crossref","first-page":"13278","DOI":"10.1021\/acsnano.3c00941","article-title":"Liquid metal nanoplatform based autologous cancer vaccines","volume":"17","author":"Wang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115888_bb1615","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1021\/acs.nanolett.4c00376","article-title":"Photoactivated formation of an extravascular dynamic hydrogel as an intelligent blood flow regulator to reprogram the immunogenic landscape","volume":"24","author":"Chen","year":"2024","journal-title":"Nano Lett"},{"key":"10.1016\/j.addr.2026.115888_bb1620","doi-asserted-by":"crossref","first-page":"14720","DOI":"10.1021\/acs.nanolett.4c03929","article-title":"Proximal Anchoring of Nanodrugs through In Situ Generated Radical Hooks with Boosted Autophagy and Immunotherapy","volume":"24","author":"Liu","year":"2024","journal-title":"Nano Lett"},{"key":"10.1016\/j.addr.2026.115888_bb1625","unstructured":"Utilizing Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) With Pleural Disease or Malignant Pleural Mesothelioma (MPM) - Phase I Study, 2021."},{"key":"10.1016\/j.addr.2026.115888_bb1630","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/j.jvir.2009.12.403","article-title":"Cryoablation: mechanism of action and devices","volume":"21","author":"Erinjeri","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.addr.2026.115888_bb1635","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.copbio.2020.01.006","article-title":"Cryoablation and immunotherapy of cancer","volume":"65","author":"Yakkala","year":"2020","journal-title":"Curr. Opinion Biotechnol."},{"key":"10.1016\/j.addr.2026.115888_bb1640","article-title":"Progress in the cryoablation and cryoimmunotherapy for tumor","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.addr.2026.115888_bb1645","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1039\/D3MH00092C","article-title":"Autologous-cancer-cryoablation-mediated nanovaccine augments systematic immunotherapy","volume":"10","author":"Yu","year":"2023","journal-title":"Mater Horiz"},{"key":"10.1016\/j.addr.2026.115888_bb1650","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/cts.12315","article-title":"Regulatory Considerations in the design and manufacturing of implantable 3d-printed medical devices","volume":"8","author":"Morrison","year":"2015","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.addr.2026.115888_bb1655","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10680","article-title":"Hydrogels in the clinic: An update","volume":"9","author":"Clegg","year":"2024","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.addr.2026.115888_bb1660","doi-asserted-by":"crossref","first-page":"879","DOI":"10.5966\/sctm.2014-0122","article-title":"Proceedings: international regulatory considerations on development pathways for cell therapies","volume":"3","author":"Feigal","year":"2014","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.addr.2026.115888_bb1665","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.19.02985","article-title":"Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST","volume":"38","author":"Goldmacher","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.addr.2026.115888_bb1670","doi-asserted-by":"crossref","DOI":"10.36922\/OR025200017","article-title":"Bone marrow microenvironment and organ chips: Advances in tumor dormancy research","volume":"1","author":"Li","year":"2025","journal-title":"Organoid Res."},{"key":"10.1016\/j.addr.2026.115888_bb1675","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1039\/D4LC01043D","article-title":"Cancer-on-a-chip for precision cancer medicine","volume":"25","author":"Liu","year":"2025","journal-title":"Lab Chip"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:51:17Z","timestamp":1780822277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26001225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":335,"alternative-id":["S0169409X26001225"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115888","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming intratumoral transport barriers: Advances in local immunotherapy delivery platforms","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115888","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115888"}}